Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY5625575 in Healthy Participants and Participants With Elevated C-Reactive Protein
NCT07801300Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of LY5625575 in inflammation (10 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Sep 2026; status: recruiting.
02
Drugs
LY5625575
03
Conditions
inflammation
Beyond the preview
Go deeper on NCT07801300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801300.